D. E. Shaw & Co., Inc. Krystal Biotech, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 49,892 shares of KRYS stock, worth $6.31 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
49,892
Previous 7,427
571.77%
Holding current value
$6.31 Million
Previous $1.16 Million
673.43%
% of portfolio
0.01%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding KRYS
# of Institutions
328Shares Held
24.3MCall Options Held
299KPut Options Held
97.6K-
Black Rock Inc. New York, NY3.95MShares$499 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.83MShares$357 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$345 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$155 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$121 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.25B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...